ReportGem ReportGem

U.S. COMPANY FILING

Moderna, Inc. — Form 10-Q filed 2026-05-01

Filed: 2026-05-01Company: Moderna, Inc.Ticker: MRNAExchange: NasdaqForm: 10-QReport period: 2026-03-31SEC accession: 0001682852-26-000060Event: earningsMateriality: 85

Filing text preview

Moderna reported Q1 2026 net loss of $1.363 billion, EPS -$3.40, total revenue $389 million (product sales $352 million, other revenue $37 million). Cash and investments totaled $7.456 billion. Entered Recordati collaboration for mRNA-3927 with $50 million upfront. Settled Arbutus/Genevant litigation with $950 million accrued liability. R&D expenses decreased, but costs remain high.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-05-01US Treasury to At Least Double Debt Buybacks; Stock Futures Climb2026-08-20Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support2026-08-20Wall St Rises as Yields Ease, Moderna Lifts Healthcare Stocks2026-08-20Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal2026-08-2010-Q2026-07-31 · 10-Q